Groundbreaking Presentation at ACC 2025

In a groundbreaking presentation at the American College of Cardiology (ACC) Scientific Session in Chicago, researchers unveiled the promising results of tirzepatide for individuals grappling with the cardiovascular-kidney-metabolic triad. The findings reveal that tirzepatide, a drug primarily used to manage diabetes and aid in weight loss, offers similar protective benefits to those suffering from chronic kidney disease (CKD) as it does to those without the condition.

SUMMIT Trial Findings

The SUMMIT trial, which focused on patients with heart failure with preserved ejection fraction (HFpEF) and a body mass index (BMI) of 30 or higher, included 441 participants with CKD. These patients experienced a notable reduction in cardiovascular events and mortality, paralleling the results of participants without CKD. This groundbreaking evidence highlights tirzepatide's potential to improve cardiac health while also showing signs of enhancing kidney function.

Research Enthusiasm